Axogen, Inc. to Report 2025 First Quarter Financial Results on May 8, 2025
Shareholders Should Be Pleased With Axogen, Inc.'s (NASDAQ:AXGN) Price
Express News | AxoGen Inc - Anticipates Minimal Impact From New US Tariffs - SEC Filing
AxoGen's Positive Investment Outlook Bolstered by Seasonal Revenue Growth and Upcoming Avance BLA Approval
Axogen, Inc.'s (NASDAQ:AXGN) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 7.7% Over Last Week
Express News | AxoGen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Press Release: Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lake Street Initiates AxoGen(AXGN.US) With Buy Rating, Announces Target Price $30
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Axogen Price Target Announced at $30.00/Share by Lake Street
Axogen Initiated at Buy by Lake Street
Analyst Expectations For Axogen's Future
Cantor Fitzgerald Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $24
CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $26
JMP Securities Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $26
AxoGen's Strategic Market Positioning and Anticipated BLA Approval Drive Buy Rating
AxoGen Reports Strong Growth and Positive Outlook
AxoGen | 10-K: FY2024 Annual Report
Axogen Is Maintained at Buy by Canaccord Genuity